Inari Medical (STU:IM7) ROCE % : -10.93% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Inari Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Inari Medical's annualized ROCE % for the quarter that ended in Mar. 2024 was -10.93%.

Inari Medical ROCE % Historical Data

The historical data trend for Inari Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inari Medical ROCE % Chart

Inari Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-0.91

12.47

4.83

-7.40

0.84

Inari Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-1.01	2.64	4.78	-2.28	-10.93

Inari Medical ROCE % Calculation

Inari Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	4.073	/	( ( (475.919 - 53.028)	+	(618.273 - 70.003) )	/ 2 )
	=	4.073	/	( (422.891	+	548.27)	/ 2 )
	=	4.073	/	485.5805
	=	0.84 %

Inari Medical's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-58.912	/	( ( (618.273 - 70.003)	+	(608.834 - 79.154) )	/ 2 )
	=	-58.912	/	( ( 548.27	+	529.68 )	/ 2 )
	=	-58.912	/	538.975
	=	-10.93 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Inari Medical (STU:IM7) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Inari Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Inari Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inari Medical (STU:IM7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inari Medical Inc (STU:IM7) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NARI:USA

Address

6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618

Website

https://www.inarimedical.com

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.

Inari Medical (STU:IM7) Headlines

No Headlines